Determination of valsartan in human plasma by HPLC

Chinese Pharmacological Bulletin

Volumn 18, Issue 5, 2002, Pages 586-588

  Xu, Yan Feng ^a   Cao, Wen ^a   Lin, Xin ^a   Ling, Shu Sen ^a  

^a Jingning Hospital   (China)

Author keywords

HPLC; TDM; Valsartan

Indexed keywords

ACETONITRILE; VALSARTAN;

ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PLASMA;

EID: 0036816814     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Dudley C, Keavney B, Casaadei B et al. Prediction of patient responses to antihypertensive drugs using genetic ploymorphisms: Investigation of reninangiotensin system genes. J Hypertens. 1996;14 (2):259-62
2. Szombathy T, Szalai C, Katalin B et al. Association of angiotensin II type 1 receptor polymorphism with resistant essential hypertension. Clin Chim Acta, 1998;269(1):91-100
3. Sioufi A, Marfil F, Godbillon J. Automated determination of an angiotensin II receptor antagonist, CGP48 933, in plasma by high performance liquid chromatography. J Liq Chromatogr, 1994;17 (10):2179-86
4. Schmidt EK, Antonin KH, Flesch G et al. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol, 1998;53(6):451-8
5. Flesh G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol, 1997;52(2):115-20
6. 1) receptor blockers in hypertansion. J Hum Hypertens, 2000;14(Suppl 1):S73-86